{"product_id":"generic-tepotinib-tepodx","title":"TEPODX (Tepotinib)","description":"\u003ch2\u003eAbout Tepotinib\u003c\/h2\u003e\u003cp\u003eTepotinib is a kinase inhibitor directed against MET, including variants with exon 14 skipping - it inhibits MET phosphorylation and subsequent downstream signaling pathways in order to inhibit tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Non-Small_Cell_Lung_Cancer\"\u003eNon–Small Cell Lung Cancer\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated for metastatic non–small cell lung cancer (NSCLC) in adults harboring mesenchymal-epithelial transition (MET) exon 14 (ex14) skipping alterations\u003c\/p\u003e\u003cp\u003e450 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eRecommended dose reduction to manage adverse reactions: 225 mg PO qDay\u003c\/p\u003e\u003cp\u003ePermanently discontinue if unable to tolerate 225 mg PO qDay\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Interstitial_lung_disease_ILD_pneumonitis\"\u003eInterstitial lung disease (ILD)\/ pneumonitis\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSuspected ILD (any grade): Withhold\u003c\/li\u003e\n\u003cli\u003eConfirmed ILD: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Increased_ASTALT_andor_total_bilirubin\"\u003eIncreased AST\/ALT and\/or total bilirubin\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_3_increased_ASTALT_without_increased_total_bilirubin\"\u003eGrade 3 increased AST\/ALT without increased total bilirubin\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to baseline ALT\/AST\u003c\/li\u003e\n\u003cli\u003eIf recovered to baseline ≤7 days, resume at same dose; otherwise, resume at a reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_3_increased_total_bilirubin_without_concurrent_increased_ASTALT\"\u003eGrade 3 increased total bilirubin without concurrent increased AST\/ALT\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to baseline total bilirubin\u003c\/li\u003e\n\u003cli\u003eIf recovered to baseline ≤7 days, resume at reduced dose; otherwise, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Permanently_discontinue\"\u003ePermanently discontinue\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eGrade 4 increased ALT\/AST without increased total bilirubin\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN with total bilirubin \u0026gt;2x ULN without cholestasis or hemolysis\u003c\/li\u003e\n\u003cli\u003eGrade 4 increased total bilirubin without concurrent increased AST\/ALT\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2: Maintain dose; if intolerable, consider withholding until resolved, then resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3: Withhold until resolved, then resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Recommended dose not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh Class A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh Class C): Pharmacokinetics and safety not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953507371,"sku":"RL3020241030","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2296.jpg?v=1787022203","url":"https:\/\/xomeds.com\/products\/generic-tepotinib-tepodx","provider":"XOMEDS","version":"1.0","type":"link"}